Skip to main content

Table 2 Treatment history and resistance in 14 patients with major PI resistance

From: It is time to consider third-line options in antiretroviral-experienced paediatric patients?

Study no

Prior Rx

Current Rx

PI resistance

TAMS

LPV/r resistance interpretation

HIVDB: resistance

to salvage PIs

     

Rega

HIVDB

ANRS

Geno2Pheno

DRV/r

TPV/r

ATV/r

138

AZT, 3TC, RTV

AZT, 3TC, LPV/r

M46I, I54V, V82A, L10F

None

Int

Int

Int

Int

None

None

Int

344

AZT, 3TC, RTV

D4T, ABC, LPV/r

L10V, L24I, K43T, M46I, I54V, T74S, V82A

M41L, D67N, K70R, T215F, K219Q

Res

Int

Res

Res

None

Pot low

Int

345

D4T, 3TC, RTV

AZT, 3TC, EFV

L10I, I54V, V82A

D67N, K70R, T215FY, K219EQ

Int

Int

Int

Int

None

None

Low

87

D4T, 3TC, RTV

AZT, 3TC, RTV

I54V, V82A, L10V, L33F

None

Int

Int

Int

Int

None

Low

Int

34

D4T, 3TC, RTV

D4T, 3TC, RTV

I54V; V82A; L10V

None

Int

Int

Int

Sens

None

None

Low

34b

 

D4T, 3TC, LPV/r

I54V; L76V; V82A; L10I, A71V

None

Res

Res

Res

Int

Low

None

Low

78

AZT, 3TC, RTV

ABC, DDI, NVP

L33F, I54V, A71V, V82S, L90M

D67N, K70R, K219E

Int

Int

Res

Int

None

Int

Int

78b

 

AZT, 3TC, LPV/r

L33F, I54V, A71V, V82S, L90M

D67N, K70R, T215I, K219E

Int

Int

Res

Int

None

Int

Int

228

AZT, 3TC, RTV

AZT, DDI, LPV/r

L10V, L23I, M46I, I54V, L76V, V82M

D67N, K70R, T215F, K219E

Res

Int

Res

Res

Low

None

Int

185

D4T, DDI, RTV

AZT, 3TC, EFV

V82A

None

Sens

Int

Sens

Sens

None

None

Low

32

D4T, 3TC, RTV

D4T, 3TC, LPV/r

I54V, V82A, L10I, T74S

None

Int

Int

Res

Int

None

None

Low

32b

 

D4T, 3TC, LPV/r

L10FI, L33F, I54V, T74S, V82A

None

Int

Int

Res

Int

None

Low

Int

94

D4T, 3TC, RTV

D4T, 3TC, LPV/r

M46I, I54V, V82A, L10F, L24I

None

Int

Int

Res

Res

None

None

Int

29

AZT, 3TC, RTV

AZT, 3TC, LPV/r

I54V

None

Sens

Sens

Sens

Sens

None

None

Pot low

38

D4T, DDI, RTV

D4T, 3TC, LPV/r

I54V; V82A; L90M; Q58E; A71V

None

Int

Int

Res

Int

None

Low

Int

324

D4T, 3TC, RTV

D4T, 3TC, LPV/r

M46V, I54V, A71V, T74S,V82A, L90M

None

Int

Int

Res

Res

None

None

Int

49

D4T, DDI, RTV

D4T, DDI, RTV

I54V; V82A; L90M; L33F; Q58E

M41L; D67N; T215Y

Int

Int

Int

Sens

None

Low

Int

  1. Rega: Rega v.8.0.2 resistance interpretation system
  2. HIVDB: The Stanford HIV Data Base v. 6.0.11 resistance interpretation system
  3. ANRS: The French ANRS v. 2011.20 resistance interpretation system
  4. Geno2Pheno: The Geno2Pheno resistance interpretation system
  5. For comparison of resistance interpretation systems, the "Sensitive, Intermediate and Resistant" (SIR) classification was used: Sens: Sensitive (high-level resistant), Int: Intermediate-level resistance, and Res: Resistant
  6. The standard HIVDB classification includes additional categories: Low: Low-level resistance, Pot low: Potential low-level resistance
  7. Prior Rx: Prior treatment
  8. Current Rx: Treatment at the time of resistance test
  9. TAMS: Thymidine-associated mutations
  10. All patients receiving 3TC at the time of resistance testing had the M184V mutation.
  11. All patients included in the table had HIV-1 genotype C pol sequences according to the Rega HIV-1 subtyping tool.
  12. Specimens labelled "b" are repeat specimens on the same patient.